Clinical Trials Browser

HER2+ Metastatic Breast Cancer (MBC) × Breast × 90 days × Clear all

NCT06983691 2026-03-06

Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

Phase NA Not yet recruiting

HER2+ Metastatic Breast Cancer (MBC)